Table 4.

Comparison of the indicators of CHFC and CHFT before and after three courses treatment (75^th)

	CHFC (n=48)		CHFT (n=48)
	Before treatment	After 75th	Before treatment	After 75th
LVEF, %	36.0±6.9	45.2±7.8*	34.9±7.8	52.8±7.3*
LVEDD, mm	60.3±9.4	57.4±8.4	63.2±6.6	54.8±6.0*
LVESD, mm	52.0±5.3	46.8±9.6	54.7±6.9	42.1±7.9*
6MWT, m	323.0±44.8	425±44.5*	322.0±37.5	466±42.0*
MLHFQ, score	49.0±22.5	29.8±16.3**	47.5±18.8	23.0±15.9**
BNP, pg/mL	4331.5±3578.6	2166.2±278.4**	4869.4±3665.8	1845.5±365.6**
hsCRP, mg/L	13.2±15.4	2.8±0.3**	15.8±15.2	2.0±0.3**
CD3+, %	56.2±11.3	65.2±14.3	54.4±10.9	75.2±15.9**
CD3+/CD4+, %	22.5±9.6	35.8±9.4*	21.5±10.6	52.7±13.6**
CD3+/CD8+, %	35.1±9.2	26.8±9.6	33.0±8.8	20.3±8.2**
CD4+/CD8+	0.6±0.9	1.1±0.3	0.6±0.8	2.3±0.34*
CD56+16+, %	9.6±12.9	13.6±2.2	11.2±11.5	19.2±3.5*
CD19+, %	12.2±6.8	14.2±3.7	12.6±5.7	19.9±4.8*
TNF-α, ng/mL	1.009±0.079	0.929±0.101	0.989±0.094	0.838±0.100*
IL-1β, ng/mL	0.228±0.044	0.208±0.074	0.218±0.027	0.181±0.032
IL-10, pg/mL	176.01±4.98	179.41±23.82	175.57±8.93	184.01±28.53
TNF-α/IL-10	5.732±0.33	5.178±0.38	5.633±0.28	4.554±0.69*

Data are expressed as mean±SD or %. Shapiro–Wilk was used for normality tests, and the variables are subjected (or approximatively subjected) to normal distribution. Paired t-test was used to determine the statistical significance of differences. Compared with before treatment,

^*P<0.05,

^**P<0.01.

BNP - plasma brain natriuretic peptide; CHF - chronic heart failure; CHFT - CHF testing group; hsCRP - plasma high sensitive C-reactive protein; IL-1β - interleukin-1-β; LVEDD - the inner diameter of left ventricular end-diastole; LVEF - ejection fraction of left ventricle; LVESD - the inner diameter of left ventricular end-systole; MLHFQ - Minnesota Living with Heart Failure Questionnaire assessment; TNF-α, tumor necrosis factor-α; 6MWT - 6-min walking distance